Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
J Med Chem ; 61(23): 10651-10664, 2018 12 13.
Article in English | MEDLINE | ID: mdl-30392371

ABSTRACT

We recently reported the identification of a GroEL/ES inhibitor (1, N-(4-(benzo[ d]thiazol-2-ylthio)-3-chlorophenyl)-3,5-dibromo-2-hydroxybenzamide) that exhibited in vitro antibacterial effects against Staphylococcus aureus comparable to vancomycin, an antibiotic of last resort. To follow up, we have synthesized 43 compound 1 analogs to determine the most effective functional groups of the scaffold for inhibiting GroEL/ES and killing bacteria. Our results identified that the benzothiazole and hydroxyl groups are important for inhibiting GroEL/ES-mediated folding functions, with the hydroxyl essential for antibacterial effects. Several analogs exhibited >50-fold selectivity indices between antibacterial efficacy and cytotoxicity to human liver and kidney cells in cell culture. We found that MRSA was not able to easily generate acute resistance to lead inhibitors in a gain-of-resistance assay and that lead inhibitors were able to permeate through established S. aureus biofilms and maintain their bactericidal effects.


Subject(s)
Amides/chemistry , Amides/pharmacology , Biofilms/drug effects , Chaperonin 10/antagonists & inhibitors , Chaperonin 60/antagonists & inhibitors , Staphylococcus aureus/drug effects , Staphylococcus aureus/physiology , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Biofilms/growth & development , HEK293 Cells , Humans , Staphylococcus aureus/growth & development
2.
J Med Chem ; 61(16): 7345-7357, 2018 08 23.
Article in English | MEDLINE | ID: mdl-30060666

ABSTRACT

Extending from a study we recently published examining the antitrypanosomal effects of a series of GroEL/ES inhibitors based on a pseudosymmetrical bis-sulfonamido-2-phenylbenzoxazole scaffold, here, we report the antibiotic effects of asymmetric analogs of this scaffold against a panel of bacteria known as the ESKAPE pathogens ( Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species). While GroEL/ES inhibitors were largely ineffective against K. pneumoniae, A. baumannii, P. aeruginosa, and E. cloacae (Gram-negative bacteria), many analogs were potent inhibitors of E. faecium and S. aureus proliferation (Gram-positive bacteria, EC50 values of the most potent analogs were in the 1-2 µM range). Furthermore, even though some compounds inhibit human HSP60/10 biochemical functions in vitro (IC50 values in the 1-10 µM range), many of these exhibited moderate to low cytotoxicity to human liver and kidney cells (CC50 values > 20 µM).


Subject(s)
Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Chaperonin 10/antagonists & inhibitors , Chaperonin 60/antagonists & inhibitors , Methicillin-Resistant Staphylococcus aureus/drug effects , Anti-Bacterial Agents/adverse effects , Bacterial Proteins/antagonists & inhibitors , Calorimetry/methods , Cell Line , Cell Survival/drug effects , Chaperonin 10/chemistry , Chaperonin 10/metabolism , Drug Evaluation, Preclinical/methods , Gram-Negative Bacteria/drug effects , Gram-Positive Bacteria/drug effects , Humans , Microbial Sensitivity Tests , Structure-Activity Relationship , Sulfonamides/chemistry , Thiophenes/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL